Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement

Pharmazie

Volumn 67, Issue 11, 2012, Pages 930-937

  Tan, S L ^a   Li, Z ^a   Song, G B ^b   Liu, L M ^b   Zhang, W ^a   Peng, J ^a   Zhang, T ^a   Jia, F F ^a   Zhou, G ^a   Zhou, H H ^a   Zhou, X M ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CARBAMAZEPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENYTOIN; THYROXINE; WARFARIN;

ADULT; ALGORITHM; ARTICLE; CEREBROVASCULAR ACCIDENT; CHINESE; COMPARATIVE STUDY; DRUG DESIGN; FEMALE; GENOTYPING TECHNIQUE; HEART VALVE REPLACEMENT; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREOPERATIVE EVALUATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; WARFARIN DOSING ALGORITHM;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DNA; FEMALE; GENOTYPE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INDIVIDUALIZED MEDICINE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; WARFARIN; YOUNG ADULT;

EID: 84869027950     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.2633     Document Type: Article

References (33)

1. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116: 2563-2570. (Pubitemid 350179221)
2. Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ (2010) CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 70: 234-240.
3. Chern HD, Ueng TH, FuYP, Cheng CW (2006) CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin Chim Acta 367: 108-113.
4. Cho HJ, On YK, Bang OY, Kim JW, Huh W, Ko JW, Kim JS, Lee SY (2011) Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clin Ther 33: 1371-1380.
5. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84: 326-331.
6. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165: 1095-1106. (Pubitemid 40720733)
7. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, Zou XM, Li Q, Ma LQ, Wang HF, Chen BL, Li L, Jia YK, Xu XM (2009) Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 19: 226-234.
8. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S, Makris M; British Committee for Standards in Haematology (2011) Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 154: 311-324.
9. Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG (2009) Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenet Genomics 19: 103-112.
10. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA, International Warfarin Pharmacogenetics Consortium (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360: 753-764.
11. Lee SJ, Jang YJ, Cha EY, Kim HS, Lee SS, Shin JG (2010) A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients. Br J Clin Pharmacol 70: 213-221.
12. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87: 572-578.
13. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium (2010)Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115: 3827-3834.
14. Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur Journal Clin Pharmacol 65: 365-375.
15. Miao L, Yang J, Huang C, Shen Z (2007) Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63: 1135-1141. (Pubitemid 350112769)
16. Ohno M, Yamamoto A, Ono A, Miura G, Funamoto M, Takemoto Y, Otsu K, Kouno Y, Tanabe T, Masunaga Y, Nonen S, Fujio Y, Azuma J (2009) Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol 65: 1097-1103.
17. Rahman M, BinEsmael TM, Payne N, Butchart EG (2006) Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother 40: 397-401.
18. Roper N, Storer B, Bona R, Fang M (2010) Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn 12: 283-291.
19. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329-2333. (Pubitemid 41510803)
20. Shin J, Cao D (2011). Comparison ofwarfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 12: 125-134.
21. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16: 101-110. (Pubitemid 43145678)
22. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113: 784-792.
23. Wallin R, Martin LF (1985). Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest 76: 1879-1884. (Pubitemid 16196058)
24. Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT, Hou ZS, Xu S, Ma SJ, Wu M, Tai S (2008) Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 396: 76-79.
25. Wells PS, Holbrook AM, Crowther NR, Hirsh J (1994) Interactions of warfarin with drugs and food. Ann Intern Med 121: 676-683.
26. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, Lee TH, Kuo CT, Sun FM, Chang YJ, Kuan PL, Chen YF, Charng MJ, Ray CY, Wu JY, Chen YT (2008) Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 84: 83-89. (Pubitemid 351861488)
27. Wysowski DK, Nourjah P, Swartz L (2007) Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167: 1414-1419. (Pubitemid 47052441)
28. You JH, Wong RS, Waye MM, Mu Y, Lim CK, Choi KC, Cheng G (2011) Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thrombosis Thrombolysis 31: 113-118.
29. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human Mol Gen 14: 1745-1751. (Pubitemid 41430097)
30. Zhang X, Li L, Ding X, Kaminsky LS (2011) Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations inwarfarin maintenance dose. Drug Metabol Dispos 39: 1433-1439.
31. Zhimin W, Yubao Z, Lei S, Xianliang Z, Wei Z, Li S, Hao W, Jianjun L, Detrano R, Rutai H (2006) Prevalence of chronic rheumatic heart disease in Chinese adults. Int J Cardiol 107: 356-359. (Pubitemid 43287781)
32. Zhong SL, Yu XY, Liu Y, Xu D, Mai LP, Tan HH, Lin QX, Yang M, Lin SG (2011) Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. Pharmacogenet Genomics 22:176-82.
33. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW (2007) Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 53: 1199-1205. (Pubitemid 47020974)